Park Sae-Gwang, Jung Jeong-Joo, Won Hae Jeong, Kang Mi Seon, Seo Su-Kil, Choi Il-Whan, Eun Choong Ki, Ahn Ki Jung, Park Cheol Woo, Lee Soo-Woong, Lew Young S, Bae Ill-Ju, Choi In-Hak
Department of Microbiology, Busanpaik Hospital, Inje University College of Medicine, 633-165 Gaegum-Dong, Jin-Gu, Busan, Republic of Korea.
Cancer Lett. 2009 May 18;277(2):212-7. doi: 10.1016/j.canlet.2008.12.012. Epub 2009 Jan 19.
Tetras (tetra-arsenic oxide, As(4)O(6)) is a derivative of arsenic used in Korean traditional medicine for the treatment of cancer, but its mechanism remains largely undefined. Recently, a similar arsenic derivative, diarsenic trioxide (As(2)O(3), ATO), has been shown to mediate anti-tumor activity, therefore reigniting interest in the therapeutic effect of arsenic compounds. Here we report that Tetras can effectively mediate an anti-vascular effect on tumors, leading to delay in tumor growth and increased survival. Our study demonstrates for the first time the potential use of Tetras as a radiation therapy enhancement agent for solid tumors. These findings reveal an unappreciated role of Tetras in cancer therapy and its potential application to radiotherapy in achieving local tumor control.
四氧化四砷（tetra-arsenic oxide, As₄O₆）是一种砷的衍生物，在韩国传统医学中用于治疗癌症，但其作用机制在很大程度上仍不明确。最近，一种类似的砷衍生物三氧化二砷（As₂O₃, ATO）已被证明可介导抗肿瘤活性，因此重新引发了人们对砷化合物治疗效果的兴趣。在此我们报告，四氧化四砷可有效介导对肿瘤的抗血管生成作用，导致肿瘤生长延迟和生存期延长。我们的研究首次证明了四氧化四砷作为实体瘤放射治疗增强剂的潜在用途。这些发现揭示了四氧化四砷在癌症治疗中未被认识到的作用及其在实现局部肿瘤控制的放射治疗中的潜在应用。
